INTRODUCTION
Pharmaceutical Industry in India has grown with tremendous pace and Indian markets are flooded with a huge number of branded formulations with large difference in the manufacturing cost of drugs and their maximum retail price and the cost of different brands of the same formulation. This apart from creating confusion among innocent consumers, often allows them to be misled by unfair traders. 1 High cost of medicines has economic implications for the patients. Prices of prescription can affect users, suppliers and most importantly payers in health care system. 2 In fact, several studies have indicated that therapeutic compliance is influenced by drug prices. 3 Thus; the cost of therapy may be a barrier in controlling high blood pressure and should be an important consideration in selecting antihypertensive medication. The prices of the different antihypertensive drugs vary, and price alone is only one factor which should be taken into account when considering drugs that should be reimbursed.
Hypertension is reported to be the fourth contributor to premature death in developed countries and the seventh in developing countries. It is a major risk factor for cardiovascular disease. Recent reports indicate that nearly 1 billion adults (more than a quarter of the world's population) had hypertension in 2000, and this is predicted to increase to 1.56 billion by 2025. Review of epidemiological studies suggests that the prevalence of hypertension in the last six decades has increased from 2% to 25% among urban residents and from 2% to 15% among the rural residents in India. 4 Hypertension is one of the most expensive diseases as far as treatment is concerned, as it generates higher health care expenses than those produced by individuals with normal blood pressure. The out of pocket expenditure in India is highest on antihypertensive drugs i.e., 64%. 5 Drug price control order (DPCO) is an order issued by the government to fix prices of drug. Once medicine is brought under DPCO, it cannot be sold at a price higher than that fixed by the government. In India, in 1979, 80-85% of the drugs in the market were under price control. The number has slowly decreased and by 2002 only 15-20% drugs were under price control. 6 The common man therefore has to shell out more money with medicine prices spinning out of his reach. 
RESULTS
The prices of a total of 21 drugs (11 single and 10 combination preparations), available in 55 different formulations were analyzed. These 55 formulations are manufactured by different pharmaceutical companies. 
DISCUSSION
Indian market is predominantly a branded generic market i.e., more than one company sells a particular drug under different brand names apart from the innovator company. Hence, the number of pharmaceutical products available in the market also is very high in the range of 60,000-70,000 products. This situation has led to greater price variation among drugs marketed. 8 Very few studies are available in Indian scenario, which compare the cost of drugs of different brands. Therefore, we decided to carry out the study which compares the cost of different brands of drug of one of the most common disorder. The drug prices available in CIIMS and IDR were compared as they are readily available source of drug information and are updated regularly. Drugs used in the management of hypertension were selected as it is one of the major causes of morbidity and mortality, and the treatment requires continuous prescription drug use.
Our findings reveal that the prices of most of the antihypertensive brands have percentage price variation above 100%, which is not acceptable situation for patients. Of 21 drugs studied, most of which are commonly prescribed, percentage price variation is very wide leading to unfair burden on the consumer.
In India, patients are paying out of their pockets for their medical bills and are not covered by insurance schemes unlike developed countries. 9 In this situation, it is prudent to revisit the costing mechanisms and the huge difference between the pricing of brands have to be regulated by concerned agencies. It is felt that physicians could provide better services and reduce costs of drugs if the information about drug prices was readily available. Studies have shown that providing a manual of comparative drug prices annotated with prescribing advice to physicians reduced their patients' drug expense. 10 The reasons for this price variation could be as follows: Currently, very few medicines are under drug prices control order. Hence, it is desired that the Government should bring all lifesaving and essential medicines under price control. Combinations of antihypertensive drugs are not included in essential drug list (EDL) which should be taken into consideration while revising the list. Due consideration must be placed on the pricing of drugs in the EDL to increase their accessibility to common people. DPCO appears to be an effective tool to keep in rein the drug prices which should be implemented for all drugs included in EDL.
Thus, this study highlights that there is a huge price variation among the antihypertensive drugs manufactured by different companies. Some measures must be taken by the Government to bring about the uniformity in the price. It will help to reduce the economic burden on the patients to some extent. 
